USP22 Recombinant Monoclonal Antibody

The USP22 recombinant monoclonal antibody is synthetically produced in vitro using a systematic approach. Initially, USP22 antibody genes are extracted from B cells isolated from immunoreactive rabbits. These genes undergo amplification and are cloned into suitable phage vectors, which are subsequently introduced into mammalian cell lines to facilitate the production of functional antibodies in significant quantities. The resulting USP22 recombinant monoclonal antibody is subjected to affinity chromatography purification. After rigorous verification, the antibody can be used in ELISA, IF, and FC applications, allowing for precise detection of human USP22 protein.

USP22 is a multifunctional protein that plays a pivotal role in epigenetic regulation by deubiquitinating histones and modulating chromatin structure. Its activities impact gene expression, cell cycle control, stem cell maintenance, DNA repair, and various aspects of development. Dysregulation of USP22 can have significant implications for diseases, including cancer.

USP22 serves as a histone deubiquitinating component of the transcription regulatory histone acetylation (HAT) complex SAGA. It catalyzes the deubiquitination of both histones H2A and H2B, thus acting as a coactivator. USP22 is recruited to specific gene promoters by activators such as MYC, where it is essential for transcription. Furthermore, it is required for nuclear receptor-mediated transactivation and cell cycle progression.

1. USP22 and CCND1 levels are correlated in patient lung and colorectal cancer samples. Our preclinical studies suggest that targeting USP22 in combination with CDK inhibitors might offer a promising approach for treating cancer patients whose tumors exhibit elevated CCND1. PMID: 30224477
2. Our findings indicate that miR-30e-5p suppresses non-small cell lung cancer (NSCLC) tumorigenesis by downregulating USP22-mediated Sirt1/JAK/STAT3 signaling. PMID: 29174979
3. USP22 plays a significant role in retinoblastoma cell proliferation/aging and apoptosis. PMID: 28682440
4. These findings identify USP22 as a novel deubiquitinase of BMI1 in glioma. PMID: 29788550
5. Our research demonstrates that USP22 mediates CRC cell chemoresistance through the Wnt/beta-catenin pathway. Reducing USP22 levels in CRC cells diminishes chemoresistance. PMID: 29689565
6. Data provided evidence that USP22, an upstream molecule of AP4, exhibits strong potential to promote colorectal cancer (CRC) metastasis, particularly CRC migration and invasion capacities, both in vitro and in vivo, by inducing EMT via AP4 activation. Moreover, USP22 and AP4 overexpression may stimulate tumor metastasis and adversely affect overall survival in CRC patients. PMID: 28427243
7. Our research provides evidence that USP22, a cancer stem cell marker, influences drug sensitivity via regulating SIRT1, offering new insights into the mechanisms of multidrug resistance in hepatocellular carcinoma. PMID: 28417539
8. Our study demonstrates that USP22 is indispensable for gastric cancer stem cell self-renewal through stabilization of BMI1. PMID: 28415621
9. Downregulation of USP22 in ATC cells impeded tumor growth and lung metastasis in vivo. PMID: 27145278
10. Studies indicate that aberrant expression of Ubiquitin-Specific Peptidase 22 (USP22) has been associated with poor cancer prognosis. PMID: 27057639
11. We demonstrated that USP22 was highly expressed in OS tissues and cell lines. Downregulation of USP22 inhibited OS cell proliferation, invasion, and EMT in vitro. In addition, downregulation of USP22 suppressed OS tumor growth and metastasis in vivo. PMID: 27983930
12. In breast cancer cell lines, USP22 increases c-Myc stability through c-Myc deubiquitination, which is closely correlated with breast cancer progression. PMID: 28160502
13. Our findings suggest that USP22 may be involved in hepatocellular carcinoma progression in cooperation with survivin. PMID: 26497847
14. These findings provide evidence that high USP22 expression might be important in tumor progression and serves as an independent molecular marker for poor hepatocellular carcinoma prognosis. PMID: 25909224
15. USP22 attenuated the invasion capacity of colon cancer cells by inhibiting the STAT3/MMP9 signaling pathway. PMID: 25902005
16. Our data indicate that USP22 may promote lung adenocarcinoma cell invasion by the induction of EMT. PMID: 25907317
17. Data show that the aggregates formed by polyQ-expanded ataxin 7 sequester ubiquitin-specific protease (USP22) through specific interactions. PMID: 26195632
18. The deubiquitinating enzyme activity of USP22 is necessary for regulating HeLa cell growth, and it promotes cell proliferation via the c-Myc/cyclin D2, BMI-1 and p53 pathways in HeLa cells. PMID: 26143114
19. ShRNA-mediated silencing of the ubiquitin-specific protease 22 gene restrained cell progression and affected the Akt pathway in nasopharyngeal carcinoma. PMID: 25482932
20. Data indicate that ubiquitin specific peptidase 22 (USP22)-mediated sirtuin 1 (SIRT1) deubiquitination inhibits STAT3 transcription factor acetylation and its transcriptional activation. PMID: 24969755
21. USP22 is overexpressed in human NSCLC tissues and cell lines. USP22 silencing downregulates MDMX protein expression and activates the p53 pathway. PMID: 25547493
22. Increased USP22 expression in colon cancer correlated with reduced uH2B expression, and this expression pattern may contribute to tumor progression. PMID: 25971547
23. Our findings suggest a potential mechanism underlying the oncogenic role of USP22 mediated by the modulation of the stability and activity of COX-2. PMID: 25817787
24. USP22 may accelerate ovarian cancer cell cycle progression via synergizing with TGFB1 to regulate the TGFB1 downstream cell cycle pathway. PMID: 25369910
25. Collectively, our study demonstrated a new function of USP22 that induces autophagy, thus leading to the poor prognosis of pancreatic cancer. PMID: 25241857
26. Results show that USP22 and FoxM1 are overexpressed in patients with pancreatic cancer and jointly involved in the development and progression of pancreatic cancer. PMID: 24993031
27. USP22 is involved in the carcinogenesis of human pharyngeal squamous cell carcinoma. PMID: 25241842
28. The overexpression of USP22 was observed to attenuate TSA-induced apoptosis in HeLa cells. PMID: 25323692
29. These results suggest that USP22 positively regulates RCAN1 levels, which would consequently affect diverse RCAN1-linked cellular processes. PMID: 25546086
30. Overexpression of USP22 in pancreatic cancer promoted cytoskeletal remodeling, upregulated expression of transcription factors to promote epithelial-mesenchymal transition, and increased cellular invasion and migration. PMID: 25070659
31. USP22 expression may play an important role in gastric carcinoma tissue. PMID: 25445209
32. Genetic studies indicate that Gcn5 and USP22 have important roles during development, which may presage important functions for these proteins in human diseases. [review] PMID: 25111486
33. USP22 overexpression may be associated with poor prognosis in patients with glioma. PMID: 24573640
34. High expression of USP22 was associated with Salivary Adenoid Cystic Carcinoma. PMID: 24466336
35. In the present study, a functional NLS and the minimal sequences required for the active targeting of USP22 to the nucleus were identified. PMID: 24802393
36. Findings define USP22 as a critical effector of tumor progression, which drives lethal phenotypes. PMID: 24197134
37. USP22 deubiquitinates and stabilizes NFATc2 protein levels thereby promoting IL2 expression. PMID: 24561192
38. In this study, we investigated the protein expression of USP22 in different cervical tissues by immunohistochemical staining and analyze the correlation between USP22 level and clinicopathologic features including patient outcome. PMID: 23979981
39. Overexpression of USP22 may contribute to the progression of SDC and thus may serve as a new molecular marker to predict the prognosis of SDC patients. PMID: 23664741
40. USP22 plays an important role in NSCLC progression at the early stage, and that overexpression of USP22 in tumor tissues could be used as a potential prognostic marker for patients with early clinical stage of NSCLC. PMID: 23361242
41. High USP22 expression is associated with papillary thyroid carcinoma. PMID: 23412977
42. Sp1 is a crucial regulator of USP22 transcription. PMID: 23300749
43. This study identified the deubiquitinating enzyme ubiquitin-specific protease 22 (USP22), a component of the deubiquitinating module (DUBm) of the SAGA transcriptional coactivating complex, as a SIRT1-interacting partner. PMID: 23382074
44. The USP22 regulates the cell cycle via the c--Myc/cyclin D2 pathway and down--regulating p15 and p21 expression in HepG2 cell. PMID: 23217440
45. This is the first study that determines the relationship between USP22 expression and prognosis in oral squamous cell carcinoma. PMID: 22880026
46. Data show that USP22 protein plays an essential role in esophageal squamous cell carcinoma (ESCC) progression and has clinical potentials as a biomarker and as an attractively therapeutic target for ESCC. PMID: 22447106
47. USP22 may act as an oncogene in CRC as it positively regulates cell cycle via both BMI-1-mediated INK4a/ARF pathway and Akt signaling pathway. PMID: 21928107
48. USP22 plays a crucial role in tumor formation and growth by regulating cell proliferation with USP22-dependent signaling pathway. PMID: 21773699
49. RNAi-mediated knockdown of the ubiquitin hydrolase, USP22, results in 2-fold higher ubH2B, and 2-fold lower transcriptional elongation at IRF1. USP22 depletion also diminishes 3'-end cleavage/polyadenylation by 2- to 3-fold. PMID: 22067483
50. Simultaneous activation of USP22 and BMI-1 may associate with GC progression and therapy failure. PMID: 21735131

Show More

Hide All

HGNC: 12621

OMIM: 612116

KEGG: hsa:23326

STRING: 9606.ENSP00000261497

UniGene: Hs.462492